A Phase III Study of Atezolizumab Immunotherapy plus Bevacizumab versus Sunitinib Alone in Patients with Previously Untreated Renal Cell Cancer

Full Title

A Phase III, Open-Label, Randomized Study of Atezolizumab(Anti-PD-L1 Antibody) in Combination with Bevacizumab Versus Sunitinib in Patients with Untreated Advanced Renal Cell Carcinoma


Bevacizumab and sunitinib are drugs approved to treat a type of kidney cancer called renal cell carcinoma. They work by inhibiting the blood vessels that tumors need to grow and spread. Atezolizumab is a form of immunotherapy. It designed to improve the immune system's ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers.

In this study, researchers are comparing the effectiveness of bevacizumab plus atezolizumab versus sunitinib alone in patients with inoperable renal cell cancer that has not yet been treated. Patients will be randomly assigned to receive one treatment or the other, but not both.

Atezolizumab is approved for treating bladder cancer; its use in this study is considered investigational. Atezolizumab and bevacizumab are given intravenously (by vein), while sunitinib is taken orally (by mouth).


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have inoperable or metastatic renal cell cancer that has not yet been treated.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Robert Motzer at 646-422-4312.